HoyleCohen’s Teva Pharmaceuticals TEVA Stock Holding History

HoyleCohen’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,025	Closed	-$90K	–	187
2020 Q1	$90K	Hold	10,025	–	–	0.02%	174
2019 Q4	$98K	Sell	10,025 -5,600	-36%	-$50K	0.02%	194
2019 Q3	$108K	Sell	15,625 -12,175	-44%	-$93.3K	0.02%	189
2019 Q2	$257K	Sell	27,800 -12,635	-31%	-$152K	0.04%	173
2019 Q1	$634K	Sell	40,435 -3,525	-8%	-$62.2K	0.11%	122
2018 Q4	$678K	Sell	43,960 -1,775	-4%	-$36.4K	0.14%	109
2018 Q3	$985K	Sell	45,735 -700	-2%	-$16.3K	0.19%	92
2018 Q2	$1.13M	Sell	46,435 -200	-0.4%	-$4.08K	0.23%	87
2018 Q1	$797K	Sell	46,635 -3,725	-7%	-$72.7K	0.16%	102
2017 Q4	$954K	Buy	+50,360	New	+$758K	0.19%	94

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HoyleCohen's TEVA Position: Q2 2020 in Review

HoyleCohen sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 10,025 shares — an estimated $90K sold.

HoyleCohen first reported a position in TEVA in Q4 2017 and held it in 10 quarters. The position peaked at $1.13M in Q2 2018. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

HoyleCohen reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
HoyleCohen sold 10,025 Teva Pharmaceuticals shares in Q2 2020, an estimated $90K.
HoyleCohen first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 10 quarters.
HoyleCohen's Teva Pharmaceuticals position peaked at $1.13M in Q2 2018.
455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on HoyleCohen's 13F filing for Q2 2020, filed 29 Jul 2020.